Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.

NCT Number	NCT07135427
Lead Sponsor	University of Alabama at Birmingham Collaborators: Alpha-1 Foundation
Conditions	Alpha 1-Antitrypsin, COPD, Antibody Deficiency
Enrollment	30 participants
Start Date	2025-09-03
Primary Completion	2027-03 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2025-11-10